FutureMed Ventures KZ, a Kazakh-American venture fund, seeks to foster Kazakhstan’s emerging role as a destination for clinical trials and bring innovative technologies to the country, said Almas Kenessary, the fund’s managing partner, in an interview with The Astana Times. He discussed the fund’s goals, a brain tissue regeneration technology it invests in, and why Kazakhstan is poised to become a reliable base for medical innovation.
Delaware-based venture fund
The fund was established in January in Delaware, the United States, and is operationally based in Kazakhstan. It capitalizes on its “unique de-risking concept.”
“In terms of strategic goals, we are a biotech, medtech-focused venture capital firm. Our unique de-risking concept significantly hastens not only Kazakh scientific progress but also global,” said Kenessary.
The fund targets promising developments in the biotech and medtech sectors. It attracts biotech and medtech companies from across the globe, particularly from the American market. Kenessary stressed one of the standout features of the firm’s approach is the ability to conduct early-stage clinical trials in Kazakhstan at a fraction of the usual cost and in a significantly shorter time frame.
Kenessary also added the fund focuses on identifying technologies in phase 2 clinical trials, where efficacy is the primary endpoint.